Some much-needed good news from Pfizer: The drug giant announced that its HIV treatment maraviroc [1] will receive accelerated review in both the U.S. and Europe. If approved, maraviroc will be the first in a new class of HIV/AIDS treatments called CCR5 antagonists that work by blocking viral entry. Release [2]
Links:
[1] http://www.fiercebiotech.com/story/spotlight-new-hiv-drugs-lower-virus-levels/2005-07-26
[2] http://www.fiercebiotech.com/node/5668